CRSP vs. KRYS, HALO, IMVT, IBRX, SWTX, IOVA, IMCR, CGON, ACLX, and RVMD
Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Krystal Biotech (KRYS), Halozyme Therapeutics (HALO), Immunovant (IMVT), ImmunityBio (IBRX), SpringWorks Therapeutics (SWTX), Iovance Biotherapeutics (IOVA), Immunocore (IMCR), CG Oncology (CGON), Arcellx (ACLX), and Revolution Medicines (RVMD). These companies are all part of the "biological products, except diagnostic" industry.
CRISPR Therapeutics (NASDAQ:CRSP) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.
CRISPR Therapeutics presently has a consensus price target of $76.29, indicating a potential upside of 40.54%. Krystal Biotech has a consensus price target of $171.00, indicating a potential upside of 7.10%. Given CRISPR Therapeutics' higher possible upside, equities research analysts plainly believe CRISPR Therapeutics is more favorable than Krystal Biotech.
CRISPR Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
CRISPR Therapeutics received 179 more outperform votes than Krystal Biotech when rated by MarketBeat users. However, 66.75% of users gave Krystal Biotech an outperform vote while only 65.61% of users gave CRISPR Therapeutics an outperform vote.
Krystal Biotech has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
CRISPR Therapeutics' return on equity of -8.09% beat Krystal Biotech's return on equity.
69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, CRISPR Therapeutics had 2 more articles in the media than Krystal Biotech. MarketBeat recorded 6 mentions for CRISPR Therapeutics and 4 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.53 beat CRISPR Therapeutics' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the news media.
Summary
Krystal Biotech beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.
Get CRISPR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CRISPR Therapeutics Competitors List
Related Companies and Tools
